Patented small molecule inhibitors of p53-MDM2 interaction

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 2, 2006, Pages 165-188

  Deng, Jinxia ^a   Dayam, Raveendra ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticancer drug; MDM2; Mutant p53; p53 MDM2 interaction; Protein protein interaction; Ubiquitin ligase inhibitor

Indexed keywords

1 PHENYLPIPERAZINE DERIVATIVE; 2 (4 CHLOROPHENYL) 4,5 DIPHENYL 2 IMIDAZOLINE; 3,4 DIBENZYLOXYPIPERIDINE DERIVATIVE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; 5 DEAZAFLAVINE DERIVATIVE; 7 NITRO 5 DEAZAFLAVIN; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINEDIONE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BORONIC ACID DERIVATIVE; CISPLATIN; CP 257042; DONEPEZIL DERIVATIVE; IMIDAZOLINE DERIVATIVE; INDOLE DERIVATIVE; LIGASE INHIBITOR; MALEIMIDE DERIVATIVE; MIRA 1; NUTLIN; NUTLIN DERIVATIVE; OXINDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PRIMA 1; PROTEIN MDM2; PROTEIN P53; SMALL MOLECULE INHIBITOR; UBIQUITIN PROTEIN LIGASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; DNA BINDING; DRUG BINDING; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; ISOMERISM; MOLECULAR SIZE; NONHUMAN; OSTEOSARCOMA; PHYSICAL CHEMISTRY; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; UBIQUITINATION;

EID: 33144462783     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.2.165     Document Type: Review

References (96)

1. CAHILLY-SNYDER L, YANG-FENG T, FRANCKE U, GEORGE DL: Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. (1987) 13:235.
2. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D, LEVINE AJ: The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 69(7):1237-1245.
3. OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL, VOGELSTEIN B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 358(6381):80-83.
4. STEFANOU DG, NONNI AV, AGNANTIS NJ et al.: p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study. Anticancer Res. (1998) 18(6B):4673-4681.
5. ZIETZ C, ROSSLE M, HAAS C et al.: MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. (1998) 153(5):1425-1433.
6. ZHELEVA DI, LANE DP, FISCHER PM: The p53-MDM2 pathway: targets for the development of new anticancer therapeutics. Mini Rev. Med. Chem. (2003) 3(3):257-270.
7. RAYBURN E, ZHANG R, HE J, WANG H: MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets (2005) 5(1):27-41.
8. YAM CH, SIU WY, AROOZ T et al.: MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res. (1999) 59(20):5075-5078.
9. BOND GL, HU W, LEVINE AJ: MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets (2005) 5(1):3-8.
10. HORIE S, ENDO K, KAWASAKI H, TERADA T: Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch. (2000) 437(1):25-30.
11. COCKER HA, HOBBS SM, TIFFIN N et al.: High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br. J. Cancer (2001) 85(11):1746-1752.
12. SUZUKI A, TOI M, YAMAMOTO Y et al.: Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn. J. Cancer Res. (1998) 89(2):221-227.
13. RODRIGUEZ-LOPEZ AM, XENAKI D, EDEN TO, HICKMAN JA, CHRESTA CM: MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells. Mol. Pharmacol. (2001) 59(1):135-143.
14. MATHEW R, ARORA S, KHANNA R et al.: Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur. J. Cancer (2002) 38(6):832-841.
15. ZHANG L, HILL RP: Hypoxia enhances metastatic efficiency by up-regulating MDM2 in KHT cells and increasing resistance to apoptosis. Cancer Res. (2004) 64(12):4180-4189.
16. IWAKUMA T, LOZANO G: MDM2, an introduction. Mol. Cancer Res. (2003) 1(14):993-1000.
17. ZHANG Z, ZHANG R: p53-Independent activities of MDM2 and their relevance to cancer therapy. Curr. Cancer Drug Targets (2005) 5(1):9-20.
18. FINLAY CA, HINDS PW, LEVINE AJ: The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 57(7):1083-1093.
19. BUOLAMWINI JK, ADDO J, KAMATH S et al.: Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr. Cancer Drug Targets (2005) 5(1):57-68.
20. WOODS DB, VOUSDEN KH: Regulation of p53 function. Exp. Cell Res. (2001) 264(1):56-66.
21. MALKIN D: The role of p53 in human cancer. J. Neurooncol. (2001) 51(3):231-243.
22. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC: p53 mutations in human cancers. Science (1991) 253(5015):49-53.
23. HOLLSTEIN M, RICE K, GREENBLATT MS et al.: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. (1994) 22(17):3551-3555.
24. HARRIS CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. (1996) 88(20):1442-1455.
25. MOMAND J, WU HH, DASGUPTA G: MDM2-master regulator of the p53 tumor suppressor protein. Gene (2000) 242(1-2):15-29.
26. CHO Y, GORINA S, JEFFREY PD, PAVLETICH NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 265(5170):346-355.
27. MCCOY M, STAVRIDI ES, WATERMAN JL et al.: Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J. (1997) 16(20):6230-6236.
28. CLORE GM, ERNST J, CLUBB R et al.: Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat. Struct. Biol. (1995) 2(4):321-333.
29. LEE W, HARVEY TS, YIN Y et al.: Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. (1994) 1(12):877-890.
30. WU H, MACIEJEWSKI MW, MARINTCHEVA et al.: Solution structure of a dynein motor domain associated light chain. Nat. Struct. Biol. (2000) 7(7):575-579.
31. JEFFREY PD, GORINA S, PAVLETICH NP: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 267(5203):1498-1502.
32. MITTL PR, CHENE P, GRUTTER MG: Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr. D Biol. Crystallogr. (1998) 54(Pt. 1):86-89.
33. JOERGER AC, ALLEN MD, FERSHT AR: Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J. Biol. Chem. (2004) 279(2):1291-1296.
34. JOERGER AC, ANG HC, VEPRINTSEV DB, BLAIR CM, FERSHT AR: Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. (2005) 280(16):16030-16037.
35. KUSSIE PH, GORINA S, MARECHAL V et al.: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 274(5289):948-953.
36. FREEDMAN DA, WU L, LEVINE AJ: Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci. (1999) 55(1):96-107.
37. GOTTIFREDI V, PRIVES C: Molecular biology. Getting p53 out of the nucleus. Science (2001) 292(5523):1851-1852.
38. CHENE P, FUCHS J, CARENA I, FURET P, GARCIA-ECHEVERRIA C: Study of the cytotoxic effect of a peptidic inhibitor of the p53-HDM2 interaction in tumor cells. FEBS Lett. (2002) 529(2-3):293-297.
39. LIN J, CHEN J, ELENBAAS B, LEVINE AJ: Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to MDM2 and the adenovirus 5 E1B 55 kD protein. Genes Dev. (1994) 8(10):1235-1246.
40. PICKSLEY SM, VOJTESEK B, SPARKS A, LANE DP: Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene (1994) 9(9):2523-2529.
41. BOTTGER A, BOTTGER V, GARCIA-ECHEVERRIA C et al.: Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol. (1997) 269(5):744-756.
42. BOTTGER V, BOTTGER A, HOWARD SF et al.: Identification of novel mdm2 binding peptides by phage display. Oncogene (1996) 13(10):2141-2147.
43. CHENE P: Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. Mol. Cancer Res. (2004) 2(1):20-28.
44. SCHON O, FRIEDLER A, FREUND S, FERSHT AR: Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J. Mol. Biol. (2004) 336(1):197-202.
45. CHEN L, YIN H, FAROOQI B et al.: p53 α-Helix mimetics antagonize p53/MDM2 interaction and activate p53. Mol. Cancer Ther. (2005) 4(6):1019-1025.
46. STOLL R, RENNER C, HANSEN S et al.: Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry (2001) 40(2):336-344.
47. DUNCAN SJ, GRUSCHOW S, WILLIAMS DH et al.: Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. (2001) 123(4):554-560.
48. ZHAO J, WANG M, CHEN J et al.: The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. (2002) 183(1):69-77.
49. KUMAR SK, HAGER E, PETTIT C et al.: Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem. (2003) 46(14):2813-2815.
50. VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303(5659):844-848.
51. GRASBERGER BL, LU T, SCHUBERT C et al.: Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. (2005) 48(4):909-912.
52. MOLL UM, PETRENKO O: The MDM2-p53 interaction. Mol. Cancer Res. (2003) 1(14):1001-1008.
53. CHENE P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer (2003) 3(2):102-109.
54. ALARCON-VARGAS D, RONAI Z: p53-MDM2 - the affair that never ends. Carcinogenesis (2002) 23(4):541-547.
55. CHENE P, FUCHS J, BOHN J et al.: A small synthetic peptide, which inhibits the p53-HDM2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. (2000) 299(1):245-253.
56. UENO M, IMAIZUMI K, SUGITA T, TAKATA I, TAKESHITA M: Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis. Int. J. Immunopharmacol. (1995) 17(7):597-603.
57. UENO M, SUGITA T, MURAKAMI T, TAKATA I: The novel anti-rheumatic drug TA-383 has a macrophage migration enhancing activity. Jpn. J. Pharmacol. (1997) 74(2):221-224.
58. MERRIMAN GH, MA L, SHUM P et al.: Synthesis and SAR of novel 4,5-diarylimidazolines as potent P2X7 receptor antagonists. Bioorg. Med. Chem. Lett (2005) 15(2):435-438.
59. VASSILEV LT: p53 activation by small molecules: application in oncology. J. Med. Chem. (2005) 48(14):4491-4499.
60. KLEIN C, VASSILEV LT: Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer (2004) 91(8):1415-1419.
61. BRESLIN HJ, KUKLA MJ, KROMIS T et al.: Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues. Bioorg. Med. Chem. (1999) 7(11):2427-2436.
62. KAMAL A, RAMESH C, SRINIVAS O et al.: Design, synthesis, and evaluation of mixed imine-amine pyrrolobenzodiazepine dimers with efficient DNA binding affinity and potent cytotoxicity. Bioorg. Med. Chem. (2004) 12(20):5427-5436.
63. KAMAL A, SRINIVAS O, RAMULU P et al.: Synthesis and DNA binding affinity of novel A-C8/C-C2-exo unsaturated alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers. Bioorg. Med. Chem. (2004) 12(16):4337-4350.
64. GREGSON SJ, HOWARD PW, HARTLEY JA et al.: Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J. Med. Chem. (2001) 44(5):737-748.
65. HIRAYAMA F, KOSHIO H, KATAYAMA N et al.: Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable Factor Xa inhibitors based on benzothiadiazine-4-one template. Bioorg. Med. Chem. (2003) 11(3):367-381.
66. KAMAL A, RAMESH G, LAXMAN N et al.: Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity. J. Med. Chem. (2002) 45(21):4679-4688.
67. KOSSAKOWSKI J, ZAWADOWSKI T, TURIO J: Synthesis of new N-substituted benzodiazepine derivatives with potential anxiolytic activity. Acta Pol. Pharm. (1997) 54(6):483-485.
68. KARP G, MANFREDI MC, GUACIARO MA et al.: Synthesis and herbicidal activity of 1H-1,4-benzodiazepine-2,5-diones. J. Agric. Food Chem. (1997) 45(2):493-500.
69. RABOISSON P, MARUGAN JJ, SCHUBERT C et al.: Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists. Bioorg. Med. Chem. Lett. (2005) 15(7):1857-1861.
70. KINOYAMA I, TANIGUCHI N, KAWAMINAMI E et al.: N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists. Chem. Pharm. Bull. (2005) 53(4):402-409.
71. KINOYAMA I, TANIGUCHI N, YODEN T et al.: Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists. Chem. Pharm. Bull. (2004) 52(11):1330-1333.
72. KHALAJ A, ADIBPOUR N, SHAHVERDI AR, DANESHTALAB M: Synthesis and antibacterial activity of 2-(4-substituted phenyl)-3(2H)-isothiazolones. Eur J. Med. Chem. (2004) 39(8):699-705.
73. YI EY, JEONG EJ, SONG HS et al.: Antiangiogenic and anti-tumor apoptotic activities of SJ-8002, a new piperazine derivative. Int. J. Oncol. (2004) 25(2):365-372.
74. YE B, CHOU YL, KARANJAWALA R et al.: Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1). Bioorg. Med. Chem. Lett. (2004) 14(3):761-765.
75. PICKSLEY SM, DART DA, MANSOOR MS, LOADMAN PM: Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein. Expert Opin. Ther. Patents (2001) 11(12):1825-1835.
76. CHENE P: p53 as drug target in cancer therapy. Expert Opin. Ther. Patents (2001) 11(6):923-935.
77. EBDRUP S, JACOBSEN P, FARRINGTON AD, VEDSO P: Structure-activity relationship for aryl and heteroaryl boronic acid inhibitors of hormone-sensitive lipase. Bioorg. Med. Chem. (2005) 13(6):2305-2312.
78. ASANO T, NAKAMURA H, UEHARA Y, YAMAMOTO Y: Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases. Chembiochem (2004) 5(4):483-490.
79. DING K, LU Y, NIKOLOVSKA-COLESKA Z et al.: Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. (2005) 127(29):10130-10131.
80. TOOGOOD PL: Inhibition of protein-protein association by small molecules: approaches and progress. J. Med. Chem. (2002) 45(8):1543-1558.
81. STIGERS KD, SOTH MJ, NOWICK JS: Designed molecules that fold to mimic protein secondary structures. Curr. Opin. Chem. Biol. (1999) 3(6):714-723.
82. SOMU RV, JOHNSON RL: Synthesis of pipecolic acid-based spiro bicyclic lactam scaffolds as beta-turn mimics. J. Org. Chem. (2005) 70(15):5954-5963.
83. CREIGHTON CJ, LEO GC, DU Y, REITZ AB: Design, synthesis, and conformational analysis of eight-membered cydic peptidomimetics prepared using ring closing metathesis. Bioorg. Med. Chem. (2004) 12(16):4375-4385.
84. KAUL R, SURPRENANT S, LUBELL WD: Systematic study of the synthesis of macrocyclic dipeptide β-turn mimics possessing 8-, 9- and 10-membered rings by ring-closing metathesis. J. Org. Chem. (2005) 70(10):3838-3844.
85. HALAB L, LUBELL WD: Effect of sequence on peptide geometry in 5-tert-butylprolyl type VI β-turn mimics. J. Am. Chem. Soc. (2002) 124(11):2474-2484.
86. ORNER BP, ERNST JT, HAMILTON AD: Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an α-helix. J. Am. Chem. Soc. (2001) 123(22):5382-5383.
87. SCHEFFNER M, NUBER U, HUIBREGTSE JM: Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature (1995) 373(6509):81-83.
88. WEISSMAN AM: Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell. Biol. (2001) 2(3):169-178.
89. TYERS M, WILLEMS AR: One ring to rule a superfamily of E3 ubiquitin ligases. Science (1999) 284(5414):601, 603-604.
90. LAI Z, YANG T, KIM YB et al.: Differentiation of HDM2-mediated p53 ubiquitination and HDM2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. USA (2002) 99(23):14734-14739.
91. YANG Y, LUDWIG RL, JENSEN JP et al.: Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 7(6):547-559.
92. BYKOV VJ, ISSAEVA N, ZACHE N et al.: Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. (2005) 280(34):30384-30391.
93. BYKOV VJ, SELIVANOVA G, WIMAN KG: Small molecules that reactivate mutant p53. Eur. J. Cancer (2003) 39(13):1828-1834.
94. FOSTER BA, COFFEY HA, MORIN MJ, RASTINEJAD F: Pharmacological rescue of mutant p53 conformation and function. Science (1999) 286(5449):2507-2510.
95. BYKOV VJ, ISSAEVA N, SHILOV A et al.: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. (2002) 8(3):282-288.
96. BYKOV VJ, ZACHEN, STRIDH H et al.: PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene (2005) 24(21):3484-3491.